Esketmine reduces the pain from propofol injection

Esketmine reduces the pain from propofol injection: a multicenter prospective trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061856

Enrollment

Unknown

Registered

2022-07-04

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor

Interventions

S group:s-ketmine

C group:saline

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–80 years; 2. ASA (American Society of Anesthesiology) I-II; 3. Able to complete all clinical data.

Exclusion criteria

Exclusion criteria: 1. Patients with central nervous system disease or craniocerebral injury; 2. Serious comorbidities (i.e., heart failure, respiratory failure, hepatic or renal failure); 3. Coagulation or immune system diaeaseor history of drug abuse were excluded from the study.

Design outcomes

Primary

Measure	Time frame
verbal rating scale;	—

Secondary

Measure	Time frame
Vital sign;induction time;intubation time;	—

Countries

China

Contacts

Public ContactWang Xiuqin

Shandong Cancer Hospital Affiliated to Shandong First Medical University

jasmine75@163.com+86 13665416586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026